115 related articles for article (PubMed ID: 21296388)
1. Clinical utility of fluorescence in situ hybridization for prediction of residual tumor after transurethral resection of bladder urothelial carcinoma.
Ding T; Wang YK; Cao YH; Yang LY
Urology; 2011 Apr; 77(4):855-9. PubMed ID: 21296388
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment.
Sagalowsky AI
Urology; 2011 Apr; 77(4):859; author reply 859-60. PubMed ID: 21477711
[No Abstract] [Full Text] [Related]
3. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
[TBL] [Abstract][Full Text] [Related]
4. The value of a second transurethral resection in evaluating patients with bladder tumors.
Herr HW
J Urol; 1999 Jul; 162(1):74-6. PubMed ID: 10379743
[TBL] [Abstract][Full Text] [Related]
5. [Repeat transurethral resection for non-muscle invasive bladder cancer].
Shen YJ; Ye DW; Yao XD; Zhang SL; Dai B; Zhu YP; Zhang HL; Zhu Y; Shi GH; Ma CG
Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):725-7. PubMed ID: 19615201
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
Danil'chenko DI; Koenig F; Riedl K; Schnorr D; Waldman A; Al-Shukri S; Loening SA
Vopr Onkol; 2003; 49(6):734-7. PubMed ID: 14976918
[TBL] [Abstract][Full Text] [Related]
7. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.
Kriegmair M; Zaak D; Rothenberger KH; Rassweiler J; Jocham D; Eisenberger F; Tauber R; Stenzl A; Hofstetter A
J Urol; 2002 Aug; 168(2):475-8. PubMed ID: 12131291
[TBL] [Abstract][Full Text] [Related]
8. Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Pro.
Herr HW
J Urol; 2011 Sep; 186(3):787-8. PubMed ID: 21788040
[No Abstract] [Full Text] [Related]
9. [Clinical value of aneusomy of chromosomes in exfoliated urothelial cells to predict the recurrence of superficial bladder cancer after complete transurethral resection].
Bao QB; Liu J; Sun HB; Su JH; Zhu JG; Lin JZ
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(8):548-51. PubMed ID: 19567078
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
11. [Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].
Zhang YG; Bi XG; Han YL; Cai Y; Xu X; Wu YP; Yang YL; Ma JH; Zhao P; Jia XM; Wang MR
Ai Zheng; 2007 Feb; 26(2):189-93. PubMed ID: 17298751
[TBL] [Abstract][Full Text] [Related]
12. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.
Krause FS; Walter B; Ott OJ; Häberle L; Weiss C; Rödel C; Wullich B; Sauer R
Anticancer Res; 2011 Mar; 31(3):985-90. PubMed ID: 21498726
[TBL] [Abstract][Full Text] [Related]
13. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
14. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
15. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?
Divrik T; Yildirim U; Eroğlu AS; Zorlu F; Ozen H
J Urol; 2006 Apr; 175(4):1258-61. PubMed ID: 16515974
[TBL] [Abstract][Full Text] [Related]
16. Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.
Akitake M; Yamaguchi A; Shiota M; Imada K; Tatsugami K; Yokomizo A; Naito S; Eto M
Anticancer Res; 2019 Aug; 39(8):4325-4328. PubMed ID: 31366524
[TBL] [Abstract][Full Text] [Related]
17. A second-look TUR in T1 transitional cell carcinoma: why?
Jakse G; Algaba F; Malmström PU; Oosterlinck W
Eur Urol; 2004 May; 45(5):539-46; discussion 546. PubMed ID: 15082193
[TBL] [Abstract][Full Text] [Related]
18. [Multiprobe FISH for enhanced prediction of recurrent bladder cancer].
Zellweger T; Benz G; Herzog M; Grilli B; Mihatsch MJ; Gasser TC; Bubendorf L
Verh Dtsch Ges Pathol; 2004; 88():194-8. PubMed ID: 16892552
[TBL] [Abstract][Full Text] [Related]
19. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
[TBL] [Abstract][Full Text] [Related]
20. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial.
Divrik RT; Sahin AF; Yildirim U; Altok M; Zorlu F
Eur Urol; 2010 Aug; 58(2):185-90. PubMed ID: 20303646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
